“Introducing the first anti-CD24 program for late-stage cancer patients in the U.S. is a very important milestone for ...

In 2009, OncoImmune’s founders identified a signal transducer molecule, CD24, which suppresses inflammation by binding to a pattern recognition receptor called Siglec10. They further determined ...